Senti Biosciences将在2025年AACR年会上展示新的细胞与基因治疗数据相关的帖子：-动脉网

Senti Biosciences to Showcase New Cell & GeneTherapy Data at AACR Annual Meeting 2025 Related posts:

GeneOnline 等信源发布 2025-04-27 11:55



可切换为仅中文







by Denisse Sandoval

由丹妮丝·桑多瓦尔

Share To

分享到

Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies with its proprietary Gene Circuit platform,

Senti Biosciences, Inc.（纳斯达克股票代码：SNTI），一家临床阶段的生物技术公司，利用其专有的基因电路平台开发下一代细胞和基因疗法，

announced

宣布

the selection of three abstracts for an oral minisymposium and poster presentations at the

为口头小型研讨会和海报展示选择的三个摘要

American Association for Cancer Research (AACR) Annual Meeting 2025

美国癌症研究协会（AACR）2025年年会

, scheduled for April 25–30, 2025, at the McCormick Place Convention Center in Chicago, IL.

，定于2025年4月25日至30日在伊利诺伊州芝加哥的麦考密克会展中心举行。

Presentations to Highlight SENTI-202 Clinical and Preclinical Data

演讲将重点介绍SENTI-202的临床和临床前数据

Senti Bio will present new clinical data from its first-in-human, multicenter study of SENTI-202, an off-the-shelf, logic-gated CAR NK cell therapy targeting CD33 and FLT3 in hematologic malignancies, including acute myeloid leukemia (AML). The organizers scheduled the oral presentation for Sunday, April 27, 2025, at 4:30 PM CST during the Clinical Trials Oral Minisymposium (Session CTMS01 – ADCs and Immuno-oncology-focused Biological Approaches).

Senti Bio 将在其首次人体多中心研究中展示 SENTI-202 的新临床数据，这是一种现成的、逻辑门控的 CAR NK 细胞疗法，靶向 CD33 和 FLT3，用于治疗血液系统恶性肿瘤，包括急性髓系白血病 (AML)。主办方安排了口头报告，时间为 2025 年 4 月 27 日星期日下午 4:30（中部标准时间），在临床试验口头小研讨会（会议 CTMS01 – ADC 和免疫肿瘤学相关的生物方法）期间进行。

They will announce the location closer to the event, and they assigned the abstract number CT041..

他们将在活动临近时公布地点，并分配了摘要编号CT041。

Researchers will share additional correlative data from the SENTI-202 study during a poster session on Tuesday, April 29, 2025, from 9:00 AM to 12:00 PM CST. This presentation is part of the “First-in-Human Phase I Clinical Trials 2” session (PO.CT01.02) and will take place in Section 48. The abstract is listed as CT143 / 9..

研究人员将在2025年4月29日星期二上午9:00至中午12:00（中部标准时间）的海报展示环节中，分享SENTI-202研究的更多相关数据。此次展示是“首次人体一期临床试验2”环节（PO.CT01.02）的一部分，将在第48展区进行。摘要编号为CT143 / 9。

Senti Biosciences will also highlight preclinical findings demonstrating that SENTI-202’s CD33 OR FLT3 NOT EMCN logic-gated gene circuit components selectively target AML cells while sparing healthy human hematopoietic stem and progenitor cells (HSC/HPCs) from off-tumor toxicity. Researchers will present this data during a poster session under the Immunology track, titled “Novel In Vivo, In Vitro, and In Silico Models” (Session PO.IM01.17), on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT in Section 38.

Senti Biosciences 还将重点展示临床前研究结果，证明 SENTI-202 的 CD33 或 FLT3 非 EMCN 逻辑门控基因电路组件能够选择性靶向急性髓系白血病 (AML) 细胞，同时避免对健康的人类造血干细胞和祖细胞 (HSC/HPCs) 产生脱靶毒性。研究人员将在免疫学分会场题为“新型体内、体外和计算机模拟模型”（Session PO.IM01.17）的海报展示环节中呈现该数据，时间为 2025 年 4 月 30 日星期三上午 9:00 至中午 12:00（中部时间），地点为第 38 展区。

They assigned the abstract number 7271 / 18..

他们分配了摘要编号 7271/18。

Advancing Gene Circuit-Enabled Cell Therapies for Hematologic and Solid Tumors with Promising Early Clinical Results

推进基因电路赋能的细胞疗法在血液和实体肿瘤中的应用，早期临床结果令人鼓舞

Senti Bio engineers its Gene Circuits to selectively kill cancer cells, spare healthy tissue, enhance target specificity, and regulate therapeutic activity after administration. The company’s pipeline includes

Senti Bio设计其基因电路以选择性杀死癌细胞，保护健康组织，提高目标特异性，并在给药后调节治疗活性。公司的研发管线包括

off-the-shelf CAR-NK cell therapies

现成的CAR-NK细胞疗法

equipped with Gene Circuits to address both liquid and solid tumors. Its lead candidate, SENTI-202, a logic-gated CD33 and/or FLT3-targeting therapy for hematologic cancers,

配备了基因电路以应对液体和实体肿瘤。其主要候选药物SENTI-202，是一种针对血液癌症的逻辑门控CD33和/或FLT3靶向疗法，

achieved

实现

MRD-negative complete remissions in two out of three patients as of September 19, 2024, with remissions sustained for more than six months as of March 20, 2025. Senti Bio

截至2024年9月19日，三名患者中有两名达到MRD阴性完全缓解，截至2025年3月20日，缓解持续超过六个月。Senti Bio

has also shown

也展示了

in preclinical studies that its Gene Circuits can function in T cells, enabling selective targeting of solid tumors, and demonstrated the potential application of Gene Circuits across other cell and gene therapy platforms and non-oncology diseases, which the

在临床前研究中，其基因电路可以在T细胞中发挥作用，实现对实体瘤的选择性靶向，并展示了基因电路在其他细胞和基因治疗平台以及非肿瘤疾病中的潜在应用，这一点

company

公司

continues to explore through internal programs and external partnerships.

通过内部项目和外部合作继续探索。

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio said, “We are excited to present updated clinical and correlative data from our ongoing SENTI-202 trial, along with detailed preclinical characterization of our Logic Gate technology. The preclinical data shows the EMCN inhibitory CAR (our NOT gate) protects healthy bone marrow cells from on-target off-tumor toxicity in vivo.

Senti Bio公司总裁、研发部门负责人兼首席医学官Kanya Rajangam博士表示：“我们很高兴展示来自我们正在进行的SENTI-202试验的更新临床和相关数据，以及我们逻辑门技术的详细临床前特性。临床前数据显示，EMCN抑制性CAR（我们的非门）在体内保护健康骨髓细胞免受靶向毒性的影响。”

Taken together, this data continues to support our enthusiasm for the potential of SENTI-202 to treat r/r AML and for Logic Gating, including our unique NOT gates, to be broadly applied to oncology to enhance the selective targeting of cancer while sparing healthy cells that may express the same targets.”.

综上所述，这些数据继续支持我们对SENTI-202治疗r/r AML的潜力以及逻辑门控（包括我们独特的“非”门）在肿瘤学中广泛应用的热情，以增强对癌症的选择性靶向，同时避免可能表达相同靶点的健康细胞受到影响。

JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center

JPM 2025年展望细胞和基因治疗领域——自身免疫、癌症和慢性疾病是关注的焦点

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

德琪医药将在2024年AACR大会上展示四项临床前研究摘要，重点突出在癌症免疫学、靶向药物和新型技术平台方面的研究。

2024 Agri-Biotechnology Leadership Awards Announced at BIO in San Diego

2024年农业生物技术领导力奖在圣地亚哥的BIO会议上揭晓

Bio Japan 2024 and Medical Japan 2024 Unleashing Innovation in Biopharmaceuticals and Healthcare Technologies

2024年生物日本和2024年医疗日本：释放生物制药和医疗技术的创新

Cross-Border Trust and Transparency: The New Landscape of Bridging the Regulatory Review in the Asia-Pacific

跨境信任与透明度：亚太地区弥合监管审查的新格局

[email protected]